OBJECTIVE: To compare the prevalence of abnormal anal cytology and high-risk human papillomavirus (HPV) among women with a history of HPV-related genital neoplasia with women without a history of HPV-related genital neoplasia. METHODS: A cross-sectional cohort study was performed from December 2012 to February 2014. Women were recruited from outpatient clinics at an academic medical center. Women with a history of high-grade cervical, vulvar, or vaginal cytology, dysplasia, or cancer were considered the high-risk group. Women with no history of high-grade anogenital dysplasia or cancer were considered the low-risk group. Human immunodeficiency virus-positive women were excluded. Anal cytology and HPV genotyping were performed. Women with abnormal anal cytology were referred for high-resolution anoscopy. RESULTS: There were 190 women in the high-risk group and 83 in the low-risk group. The high-risk group was slightly older: 57 years compared with 47 years (P=.045); 21.7% of low-risk women had abnormal anal cytology compared with 41.2% of high-risk women (P=.006). High-risk HPV was detected in the anal canal of 1.2% of the low-risk group compared with 20.8% of the high-risk group (P<.001). Among women who underwent anoscopy, no anal dysplasia was detected in the low-risk group, whereas 13.4% in the high-risk group had anal dysplasia with 4.2% having anal intraepithelial neoplasia 2 or greater (P<.001). CONCLUSION: Human immunodeficiency virus-negative women with a history of lower genital tract neoplasia are more likely to have positive anal cytology, anal high-risk HPV, and anal intraepithelial neoplasia. Anal cancer screening should be considered for these high-risk women. LEVEL OF EVIDENCE: II.
OBJECTIVE: To compare the prevalence of abnormal anal cytology and high-risk human papillomavirus (HPV) among women with a history of HPV-related genital neoplasia with women without a history of HPV-related genital neoplasia. METHODS: A cross-sectional cohort study was performed from December 2012 to February 2014. Women were recruited from outpatient clinics at an academic medical center. Women with a history of high-grade cervical, vulvar, or vaginal cytology, dysplasia, or cancer were considered the high-risk group. Women with no history of high-grade anogenital dysplasia or cancer were considered the low-risk group. Human immunodeficiency virus-positive women were excluded. Anal cytology and HPV genotyping were performed. Women with abnormal anal cytology were referred for high-resolution anoscopy. RESULTS: There were 190 women in the high-risk group and 83 in the low-risk group. The high-risk group was slightly older: 57 years compared with 47 years (P=.045); 21.7% of low-risk women had abnormal anal cytology compared with 41.2% of high-risk women (P=.006). High-risk HPV was detected in the anal canal of 1.2% of the low-risk group compared with 20.8% of the high-risk group (P<.001). Among women who underwent anoscopy, no anal dysplasia was detected in the low-risk group, whereas 13.4% in the high-risk group had anal dysplasia with 4.2% having anal intraepithelial neoplasia 2 or greater (P<.001). CONCLUSION:Human immunodeficiency virus-negative women with a history of lower genital tract neoplasia are more likely to have positive anal cytology, anal high-risk HPV, and anal intraepithelial neoplasia. Anal cancer screening should be considered for these high-risk women. LEVEL OF EVIDENCE: II.
Authors: Chunqing Lin; Jiri Slama; Paula Gonzalez; Marc T Goodman; Ningshao Xia; Aimée R Kreimer; Ting Wu; Nancy A Hessol; Yurii Shvetsov; Ana P Ortiz; Beatriz Grinsztejn; Anna-Barbara Moscicki; Isabelle Heard; María Del Refugio González Losa; Erna M Kojic; Maarten F Schim van der Loeff; Feixue Wei; Adhemar Longatto-Filho; Zizipho A Mbulawa; Joel M Palefsky; Annette H Sohn; Brenda Y Hernandez; Katina Robison; Steve Simpson; Lois J Conley; Alexandra de Pokomandy; Marianne A B van der Sande; Racheal S Dube Mandishora; Lays P B Volpini; Alessandra Pierangeli; Byron Romero; Timothy Wilkin; Silvia Franceschi; Carmen Hidalgo-Tenorio; Reshmie A Ramautarsing; Ina U Park; Fernanda K Tso; Sheela Godbole; Kathleen W M D'Hauwers; Borek Sehnal; Lynette J Menezes; Sandra A Heráclio; Gary M Clifford Journal: Lancet Infect Dis Date: 2019-06-13 Impact factor: 25.071
Authors: Joël Fokom Domgue; Craig Messick; Andrea Milbourne; Ming Guo; Mila P Salcedo; Kristina R Dahlstrom; Elizabeth Y Chiao; Ashish A Deshmukh; Erich M Sturgis; Kathleen M Schmeler Journal: Gynecol Oncol Date: 2019-03-01 Impact factor: 5.482
Authors: M Power Foley; M E Kelly; C Kerr; C Kennedy; D Gallagher; C Gillham; B J Mehigan; P H McCormick; C Bergin; J O Larkin Journal: Int J Colorectal Dis Date: 2020-06-04 Impact factor: 2.571